On Nov 06, major Wall Street analysts update their ratings for $Apellis Pharmaceuticals (APLS.US)$, with price targets ranging from $30 to $75.
J.P. Morgan analyst Anupam Rama maintains with a buy rating.
BofA Securities analyst Tazeen Ahmad maintains with a buy rating, and adjusts the target price from $61 to $47.
Citi analyst Yigal Nochomovitz maintains with a buy rating, and adjusts the target price from $63 to $51.
Wells Fargo analyst Derek Archila maintains with a hold rating, and maintains the target price at $30.
TD Cowen analyst Phil Nadeau maintains with a buy rating, and adjusts the target price from $95 to $60.
Furthermore, according to the comprehensive report, the opinions of $Apellis Pharmaceuticals (APLS.US)$'s main analysts recently are as follows:
Following the Q3 report, there is acknowledgment of a significant opportunity to develop a robust 'post-GA' investment thesis. This perspective is heavily rooted in the compelling data for C3G and IC-MPGN, which are believed to surpass that of oral competitors in a wider context.
Following Apellis' report of Q3 Syfovre revenues falling short of expectations, clarity is still sought regarding the magnitude of the geographic atrophy (GA) market. Nevertheless, the current valuation appears to undervalue the prospective scale of the opportunity. Moreover, the anticipated introduction in C3G/IC-MPGN may counterbalance the more gradual expansion in the GA segment.
The firm notes that Apellis reported a Q3 topline of $196.8M, which did not meet either the firm's estimation of $202.2M or the consensus estimate of $201M. This shortfall was attributed to higher G/N adjustments and a lower count of Syfovre vials compared to their expectations.
The perception that the GA market is experiencing a slowdown was reinforced by the third quarter performance, which necessitates a recalibration of Syfovre estimates. The anticipation of progressively less favorable commentary on pricing, coupled with a more measured approach to reaching peak levels, is expected to exert ongoing pressure on the stock's performance. It is advised that investors remain cautious about initiating positions in the stock at this time.
The company experienced some challenges from competitive dynamics, as evidenced by its Q3 revenue report of $196.8M, which was slightly below the consensus estimate of $200M. There was a year-over-year growth of 7% for Syfovre, although there was a sequential dip due to increased competition and market share shifts favoring Izervay after the latter received its permanent J-Code in April. Despite these short-term pressures, there is a belief in the significant untapped value over the long term for these products, but this situation has made the company's progress hinge on its ability to deliver results consistently, necessitating a degree of patience from investors.
Here are the latest investment ratings and price targets for $Apellis Pharmaceuticals (APLS.US)$ from 10 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間11月6日，多家華爾街大行更新了$Apellis Pharmaceuticals (APLS.US)$的評級，目標價介於30美元至75美元。
摩根大通分析師Anupam Rama維持買入評級。
美銀證券分析師Tazeen Ahmad維持買入評級，並將目標價從61美元下調至47美元。
花旗分析師Yigal Nochomovitz維持買入評級，並將目標價從63美元下調至51美元。
富國集團分析師Derek Archila維持持有評級，維持目標價30美元。
TD Cowen分析師Phil Nadeau維持買入評級，並將目標價從95美元下調至60美元。
此外，綜合報道，$Apellis Pharmaceuticals (APLS.US)$近期主要分析師觀點如下：
根據Q3報告，認識到開發強大的「GA後」投資論點具有重要機會。這一觀點主要基於C3G和IC-MPGN的引人注目的數據，相信在更廣泛的背景下將超越口服競爭對手。
根據Apellis關於Q3 Syfovre營業收入未達預期的報告，仍在尋求關於地理性萎縮（GA）市場規模的明確性。儘管如此，目前的估值似乎低估了潛在機會的規模。此外，預計C3G/IC-MPGN的推出可能會抵消GA領域增長速度更爲漸進的情況。
公司指出，Apellis報告的Q3總收入爲19680萬美元，未達到公司對20220萬美元或市場共識估值20100萬美元的預期。這一差距被歸因於較高的G/N調整和Syfovre小瓶數量低於預期。
GA市場正在放緩的看法在第三季度業績中得到了強化，這需要重新調整對Syfovre的估計。對定價越來越不利的評論以及更謹慎地達到峯值水平的預期，預計將對該股的表現施加持續壓力。建議投資者在此時對該股持謹慎態度。
公司在競爭動態中遇到了一些挑戰，其Q3營業收入報告爲19680萬美元，略低於市場估值20000萬美元。Syfovre增長了7%，儘管由於競爭加劇和市場份額轉移偏向Izervay，導致季度環比下降，後者在4月獲得永久J-Code後。儘管面臨短期壓力，但對這些產品長期未被利用的價值有信心，但這種情況使得公司的進展取決於其能夠持續交付成果，因此需要投資者保持耐心。
以下爲今日10位分析師對$Apellis Pharmaceuticals (APLS.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
